[1]宋昆鹏,石海莉,郭素萍,等.新活素治疗低心排血量综合征的效果观察[J].医学信息,2019,(20):136-138.[doi:10.3969/j.issn.1006-1959.2019.20.042]
 SONG Kun-peng,SHI Hai-li,GUO Su-ping,et al.Effect of Neonatal on Low Cardiac Output Syndrome[J].Medical Information,2019,(20):136-138.[doi:10.3969/j.issn.1006-1959.2019.20.042]
点击复制

新活素治疗低心排血量综合征的效果观察()
分享到:

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
期数:
2019年20期
页码:
136-138
栏目:
药物与临床
出版日期:
2019-10-15

文章信息/Info

Title:
Effect of Neonatal on Low Cardiac Output Syndrome
文章编号:
1006-1959(2019)20-0136-03
作者:
宋昆鹏1石海莉1郭素萍2张晶晶1李 艳1秦 立1韩 凌1陈瑞雪1
(1.郑州大学附属郑州中心医院心内二科,河南 郑州 450000;2.河南省人民医院CCU病区,河南 郑州 450000)
Author(s):
SONG Kun-peng1SHI Hai-li1GUO Su-ping2ZHANG Jing-jing1LI Yan1QIN Li1HAN Ling1CHEN Rui-xue1
(1.Department of Cardiology,Subject Two,Zhengzhou Central Hospital Affiliated to Zhengzhou University,Zhengzhou 450000,Henan,China;2.CCU Ward of Henan Provincial People's Hospital,Zhengzhou 450000,Henan,China)
关键词:
新活素低心排血量综合征心脏指数血肌酐心率
Keywords:
NeonatalLow cardiac output syndromeCardiac indexSerum creatinineHeart rate
分类号:
R654.2
DOI:
10.3969/j.issn.1006-1959.2019.20.042
文献标志码:
A
摘要:
目的 观察新活素(重组人脑利钠肽)治疗低心排血量(CO)综合征患者的临床疗效。方法 收集2018年1月~2019年1月在我院心血管内科、CCU和河南省人民医院CCU住院的低心排血量综合征患者189例,采用随机数字表法分为常规治疗组和新活素治疗组。常规治疗组患者接受常规治疗,新活素治疗组患者在常规治疗组基础上加用新活素治疗,比较两组治疗前后收缩压、舒张压、心率、血肌酐水平、心脏指数、NT-pro-BNP及尿量。结果 治疗后,两组患者心率、收缩压、舒张压、血肌酐、心脏指数等指标均较治疗前改善,差异有统计学意义(P<0.05);新活素治疗组患者心脏指数、NT-proBNP、尿量分别为(2.81±0.46)L/(min·m2)、(452.53±62.13)pg/ml、(1206.56±64.52)ml/24h,均优于常规治疗组的(2.42±0.69)L/(min·m2)、(525.23±66.25)pg/ml、(836.52±59.32)ml/24h,差异有统计学意义(P<0.05);两组收缩压、舒张压、血肌酐比较,差异无统计学意义(P>0.05)。结论 在常规治疗低心排血量综合征基础上,给予新活素治疗,可以提高低心排血量综合征的疗效,改善患者生活质量,减少住院时间。
Abstract:
Objective To observe the clinical efficacy of neonatal (recombinant human brain natriuretic peptide) in the treatment of patients with low cardiac output (CO) syndrome. Methods A total of 189 patients with low cardiac output syndrome who were admitted to the Department of Cardiology, CCU and CCU of Henan Provincial People's Hospital from January 2018 to January 2019 were enrolled. The patients were randomly divided into the conventional treatment group and the new one. The active treatment group. Patients in the conventional treatment group received routine treatment. Patients in the neonatal treatment group were treated with neomycin in the conventional treatment group. The systolic blood pressure, diastolic blood pressure, heart rate, serum creatinine level, cardiac index,NT-pro-BNP and urine output.Results After treatment, the heart rate, systolic blood pressure, diastolic blood pressure, serum creatinine and cardiac index of the two groups were improved compared with those before treatment,the difference was statistically significant (P<0.05). The cardiac index, NT-pro-BNP and urine volume of the neonatal treatment group were (2.81±0.46) L/(min·m2),(452.53±62.13) pg/ml,(1206.56±64.52) ml/24h,respectively,which were better than (2.42±0.69) L/(min·m2), (525.23±66.25) pg/ml, (836.52±59.32) ml/24h in the conventional treatment group,the difference was statistically significant (P<0.05). There was no significant difference in systolic blood pressure, diastolic blood pressure and serum creatinine between the two groups (P>0.05).Conclusion On the basis of conventional treatment of low cardiac output syndrome, neonatal therapy can improve the efficacy of low cardiac output syndrome, improve patients' quality of life and reduce hospitalization time.

参考文献/References:

[1]王锋.新活素联合左西孟旦治疗难治性心力衰竭的临床研究[J].中国医药指南,2019(13):8-9. [2]李刚.重组人脑利钠肽(新活素)联合呋塞米治疗急性左心衰临床疗效观察[J].北方药学,2019,16(5):58-59. [3]汤迎春.新活素治疗急性心肌梗死合并心力衰竭患者的护理体会[J].中国实用医药,2019,14(11):147-149. [4]董秋菊,王雄,乔占瑞,等.芪苈强心胶囊联合重组人脑利钠肽治疗射血分数中间值心力衰竭患者的临床观察[J].中国药物与临床,2018,18(5):775-777. [5]何绍礼.新活素对急性心肌梗死患者内皮功能影响的临床研究[J].中西医结合心血管病电子杂志,2019,7(10):73,76. [6]Ochiai ME,Cardoso JN,Vieira KR,et al.Predictors of low cardiac output in decompensated severe heart failure[J].Clinics (Sao Paulo),2011,66(2):239-244. [7]Torrado H,Lopez-Delgado JC,Farrero E,et al.Five-year mortality in cardiac surgery patients with low cardiac output syndrome treated with levosimendan:prognostic evaluation of NT-proBNP and C-reactive protein[J].Minerva Cardioangiol,2016,64(2):101-113. [8]Vilela EM,Bettencourt-Silva R,Nunes JP,et al.BNP and NT-proBNP elevation after running-a systematic review[J].Acta Cardiol,2015,70(5):501-509. [9]Balion CM,Santaguida P,McKelvie R,et al.Physiological,pathological,pharmaeological,biochemical and hematologica factors afecting BNP and NT-pro BNP[J].Clinical Biochemistry,2008,41(4):231-239.

更新日期/Last Update: 2019-10-15